K2M’s RHINE™ Cervical Disc received approval under the CE Mark.
RHINE comprises a 1-piece compressible polymer core with dome-shaped, plasma-coated metal endplates and a central-split keel, and is manufactured with a proprietary overmolding process intended to minimize wear between the core and endplates.
Initial single- and multi-level procedures have been completed in the EU, where enrollment for a 166-patient prospective, observational clinical study will begin in 1Q16.
Source: K2M, Inc.
In its 3Q15 revenue call, K2M affirmed that it intends to target ex-U.S. markets initially to gauge performance and interest in the RHINE disc.
The EU trial is an open label, multi-center study of patients requiring surgical treatment at one or two contiguous cervical levels. Primary objectives are to:
- obtain operative data and feedback on surgical instruments and surgical technique
- confirm device performance in terms of clinical and radiographic outcomes
- confirm device performance in terms of safety and to collect original data to be compared to published reports of the performance of comparable motion-sparing devices, as well as clinical outcomes of fusion devices.
ORTHOWORLD estimates placed the 2013 artificial disc replacement market at a 3% share of the global spine market (excluding biologics). Of that, cervical discs accounted for 70%. (Source: CERVICAL AND LUMBAR ARTIFICIAL DISC PROFILES, October 2014)
K2M's RHINE™ Cervical Disc received approval under the CE Mark.
RHINE comprises a 1-piece compressible polymer core with dome-shaped, plasma-coated metal endplates and a central-split keel, and is manufactured with a proprietary overmolding process intended to minimize wear between the core and endplates.
Initial single- and multi-level...
K2M’s RHINE™ Cervical Disc received approval under the CE Mark.
RHINE comprises a 1-piece compressible polymer core with dome-shaped, plasma-coated metal endplates and a central-split keel, and is manufactured with a proprietary overmolding process intended to minimize wear between the core and endplates.
Initial single- and multi-level procedures have been completed in the EU, where enrollment for a 166-patient prospective, observational clinical study will begin in 1Q16.
Source: K2M, Inc.
In its 3Q15 revenue call, K2M affirmed that it intends to target ex-U.S. markets initially to gauge performance and interest in the RHINE disc.
The EU trial is an open label, multi-center study of patients requiring surgical treatment at one or two contiguous cervical levels. Primary objectives are to:
- obtain operative data and feedback on surgical instruments and surgical technique
- confirm device performance in terms of clinical and radiographic outcomes
- confirm device performance in terms of safety and to collect original data to be compared to published reports of the performance of comparable motion-sparing devices, as well as clinical outcomes of fusion devices.
ORTHOWORLD estimates placed the 2013 artificial disc replacement market at a 3% share of the global spine market (excluding biologics). Of that, cervical discs accounted for 70%. (Source: CERVICAL AND LUMBAR ARTIFICIAL DISC PROFILES, October 2014)
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.





